Elanco Animal Health (NYSE:ELAN) Shares Down 4.6%
Elanco Animal Health Incorporated (New York Stock Exchange: Elan – Get a free reportThe company’s share price fell by 4.6% during trading on Friday. The company traded as low as $12.94 and last traded at $12.94. 1,947,957 shares were traded during midday trading, a decrease of 55% from the average session volume of 4,348,066 shares. The stock had previously closed at $13.57.
Wall Street analysts expect growth
A number of brokerages have recently commented on ELAN. Goldman Sachs Group raised their price target on shares of Elanco Animal Health from $12.50 to $14.00 and gave the company a “sell” rating in a report on Tuesday, February 27th. Barclays raised their price target on shares of Elanco Animal Health from $18.00 to $19.00 and gave the company an “overweight” rating in a report on Tuesday, February 27th. Stifel Nicolaus raised shares of Elanco Animal Health from a “hold” rating to a “buy” rating and increased their target price for the company from $13.00 to $20.00 in a report on Friday, January 5th. TheStreet raised shares of Elanco Animal Health from a “d+” rating to a “c-” rating in a report on Friday, February 23rd. Finally, Morgan Stanley raised their target price on shares of Elanco Animal Health from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $16.71.
Read our latest research report on Elanco animal health
Elanco animal health price performance
The company has a current ratio of 2.75, a quick ratio of 1.35 and a debt-to-equity ratio of 0.92. The company has a market cap of $6.38 billion, a P/E ratio of -5.18, a price-to-earnings-growth ratio of 1.42 and a beta of 1.29. The stock’s 50 day moving average is $15.66 and its two-hundred day moving average is $13.67.
Elanco Animal Health (New York Stock Exchange: Elan – Get a free report) published its latest quarterly earnings data on Monday, February 26th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by $0.02. The company achieved revenues of $1.04 billion during the quarter, compared to analysts’ expectations of $1 billion. Elanco Animal Health had a positive return on equity of 6.44% and a negative net margin of 27.87%. Business revenues for the quarter increased by 5.1% compared to the same quarter last year. During the same period last year, the company achieved earnings of $0.19 per share. On average, stock analysts expect Elanco Animal Health Incorporated to post 0.91 earnings per share for the current year.
Insider Transactions at Elanco Animal Health
In related news, Director R. David Hoover Bought 20,000 shares of Elanco Animal Health stock in a transaction dated Wednesday, March 6th. The shares were purchased at an average cost of $16.14 per share, for a total value of $322,800.00. Following the completion of the transaction, the director now owns 185,000 shares in the company, valued at approximately $2,985,900. The purchase was disclosed in a filing with the Securities and Exchange Commission, which can be accessed here this link. Corporate insiders own 6.40% of the company’s shares.
Hedge funds influence animal health at Elanco
A number of institutional investors have recently modified their holdings of ELAN. JPMorgan Chase & Co. Increased its position in Elanco Animal Health shares by 15.6% during the first quarter. JPMorgan Chase & Co. owns 355,004 shares of the company’s stock are now worth $9,262,000 after acquiring an additional 47,881 shares during the period. American Century Companies Inc. Its stake in Elanco Animal Health shares increased by 11.8% during the first quarter. American Century Companies Inc. owns 32,218 shares of the company’s stock are now worth $841,000 after purchasing an additional 3,396 shares in the last quarter. US Bancorp DE boosted its stake in shares of Elanco Animal Health by 17.5% during the first quarter. US Bancorp DE now owns 16,263 shares of the company’s stock valued at $425,000 after purchasing an additional 2,419 shares in the last quarter. Private Advisor Group LLC purchased a new position in shares of Elanco Animal Health during the first quarter worth approximately $333,000. Finally, MetLife Investment Management LLC purchased a new position in shares of Elanco Animal Health during the first quarter worth approximately $232,000. 97.48% of the shares are owned by hedge funds and other institutional investors.
About Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures and markets products for pets and farm animals. Offers pet health disease prevention products, such as parasiticides and vaccine products that protect pets from worms, fleas and ticks under the Seresto, Advantage, Advantix and Advocate brands; pet health treatments for pain, osteoporosis, ear infections, cardiovascular diseases, and skin conditions in canines and cats under the Galliprant and Claro brands; Vaccines, antibiotics, parasiticides, and other products used in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; A range of vaccines, antibiotics, implants, parasiticides and other products used in the production of ruminants and pigs under the brands Rumensin and Baytril.
Featured stories
Get Elanco Animal Health news and reviews daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Elanco Animal Health and related companies MarketBeat.com’s free daily email newsletter.
